Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$43.98

 1.14 (2.53%)

High$45.95
Low$42.58
Volume1,526,386
Market Cap$6,340,102,269

08/25/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 08/01/16

Read more

Seattle Genetics Reports Second Quarter 2016 Financial Results 07/26/16

Read more

Events

2nd Quarter 2016 Financial Results07/26/16 4:30 p.m. ETView eventUBS Global Healthcare Conference05/24/16 10:30 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources